Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 153,513 | 181,325 | 158,320 | 411,535 | 501,142 |
| Marketable Securities | 405,313 | 469,289 | 627,265 | 499,950 | 246,835 |
| Receivables | 58,293 | 33,616 | 30,590 | 38,593 | 160,576 |
| Other current assets | 111,113 | 67,140 | 55,810 | 75,413 | 21,247 |
| TOTAL | $728,232 | $751,370 | $871,985 | $1,025,491 | $929,800 |
| Non-Current Assets | |||||
| PPE Net | 428,003 | 340,429 | 287,696 | 217,255 | 111,616 |
| Investments And Advances | 62,580 | 82,297 | 65,938 | 72,522 | 50,313 |
| Intangibles | 86,187 | 89,919 | 168,231 | 179,308 | 196,198 |
| Other Non-Current Assets | 51,948 | 96,538 | 94,244 | 46,331 | 30,642 |
| TOTAL | $628,718 | $609,183 | $616,109 | $515,416 | $388,769 |
| Total Assets | $1,356,950 | $1,360,553 | $1,488,094 | $1,540,907 | $1,318,569 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 50,781 | 63,091 | 100,055 | 96,708 | 54,951 |
| Accrued Expenses | N/A | N/A | N/A | N/A | 22,506 |
| TOTAL | $64,307 | $76,612 | $119,013 | $118,320 | $120,676 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 13,526 | 13,521 | 18,958 | 21,612 | 7,536 |
| Other Non-Current Liabilities | 142,171 | 67,912 | 82,041 | 95,815 | 74,032 |
| TOTAL | $325,739 | $227,857 | $216,763 | $189,310 | $172,160 |
| Total Liabilities | $390,046 | $304,469 | $335,776 | $307,630 | $292,836 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 303,161 | 297,988 | 292,782 | 287,686 | 283,924 |
| Common Shares | 802,341 | 777,171 | 753,199 | 734,365 | 722,430 |
| Retained earnings | -29,482 | 116,930 | 279,787 | 426,185 | 267,666 |
| Other shareholders' equity | -4,234 | -4,378 | -1,720 | -1,391 | 280 |
| TOTAL | $966,904 | $1,056,084 | $1,152,318 | $1,233,277 | $1,025,733 |
| Total Liabilities And Equity | $1,356,950 | $1,360,553 | $1,488,094 | $1,540,907 | $1,318,569 |